Please ensure Javascript is enabled for purposes of website accessibility

A Plan to Use Blockchain to Stop Counterfeit Drugs Moves Forward

By Taylor Carmichael – Feb 21, 2020 at 1:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A host of major healthcare companies and drug retailers are collaborating on a system to combat fake drugs.

On Friday, the MediLedger Project -- a working group whose members include two dozen of the largest companies involved in healthcare  -- submitted its final report to the Food and Drug Administration for a pilot project that will use blockchain to secure the pharmaceutical supply chain.

The collaborative effort is a who's who of the healthcare industry, with participation from AmerisourceBergen (ABC -2.01%)Amgen (AMGN -0.34%)Eli Lily (LLY 0.19%)Gilead Sciences (GILD -1.43%)GlaxoSmithKline (GSK -2.17%)McKesson (MCK -1.06%)Novartis (NVS -1.47%)Novo Nordisk (NVO -0.39%)Pfizer (PFE -1.10%)Roche (RHHBY -1.10%)Sanofi (SNY -1.87%)Walgreens Boots Alliance (WBA -1.47%), and Walmart (WMT -2.50%)

The blockchain technology the project uses was created by a private company, Chronicled, in 2017.  Chronicled is tiny -- its last funding raise was for $16 million -- but it has huge ambitions. The MediLedger Project might one day secure the distribution chain for the entire $1 trillion pharmaceutical industry.

blockchain visual

Image source: Getty Images

Stopping counterfeit drugs.    

The World Health Organization estimates that counterfeit drugs cost the healthcare industry approximately $75 billion in revenues every year. Worse, counterfeit medications can kill the patients who take them.

In 2013, Congress passed the Drug Supply Chain Security Act (DSCSA). Its goal was to protect and secure drug supply chains in order to prevent counterfeits from slipping into the market unnoticed. Pharmaceutical companies must meet the federal requirements for supply chain security.

"We are very pleased that companies across the industry joined Chronicled in the MediLedger FDA Pilot Project," Chronicled CEO Susanne Somerville said. "We were able to show that a blockchain solution is feasible to meet the 2023 DSCSA requirements and are privileged to take part in making the US drug supply chain safer for patients."  

Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool recommends Amgen, McKesson, and Novo Nordisk. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$44.08 (-1.10%) $0.49
Walmart Stock Quote
$130.06 (-2.50%) $-3.33
Sanofi Stock Quote
$38.40 (-1.87%) $0.73
Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$62.86 (-1.43%) $0.91
Amgen Inc. Stock Quote
Amgen Inc.
$226.97 (-0.34%) $0.78
Roche Holding AG Stock Quote
Roche Holding AG
$39.60 (-1.10%) $0.44
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
$32.83 (-1.47%) $0.49
GSK Stock Quote
$29.36 (-2.17%) $0.65
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
$97.93 (-0.39%) $0.38
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$311.46 (0.19%) $0.59
McKesson Corporation Stock Quote
McKesson Corporation
$343.27 (-1.06%) $-3.69
AmerisourceBergen Corporation Stock Quote
AmerisourceBergen Corporation
$137.20 (-2.01%) $-2.81
Novartis AG Stock Quote
Novartis AG
$76.01 (-1.47%) $-1.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.